Start-up Epiomed Closes First Round for Anti-Emetic Work
By Jennifer Boggs
Tuesday, June 7, 2011
The work at Epiomed Therapeutics Inc. dates back to NASA's efforts back in the 1980s to reduce motion sickness on the space shuttle, but the semivirtual biotech start-up has tweaked those early discoveries and set its sights on the multi-billion-dollar nausea and vomiting market.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.